In 2013, a paper in the New England Journal of Medicine stopped the gastroenterology world in its tracks. Researchers gave patients with recurrent Clostridioides difficile infection either a standard course of vancomycin or a transplant of filtered stool from a healthy donor.
Vancomycin — the antibiotic considered the gold standard — cured 31% of patients. The donor stool infusion cured 81% after a single treatment and roughly 90% after a second. The trial was stopped early because it would have been unethical to withhold the clearly superior treatment.
This was fecal microbiota transplant (FMT). And nearly a decade later, the FDA made it official.
How FMT Works: Stool Processing, Delivery Routes & Microbiome Engraftment
FMT is conceptually simple and biologically profound: take stool from a healthy, rigorously screened donor, process it into a therapeutic preparation, and deliver it into the gut of a patient whose microbiome has collapsed. The goal is microbial ecosystem restoration — not just adding one or two probiotic strains, but transplanting hundreds of species simultaneously.
Stool Processing and Preparation
In clinical settings, donor stool is mixed with a sterile saline solution, then filtered to remove undigested food particles while retaining the microbial content — bacteria, archaea, fungi, viruses, and metabolites. The result is a microbial slurry that can be used fresh (within hours) or cryopreserved for later use.
FDA-approved products like Rebyota (RBX2660) and Vowst (formerly SER-109) take different approaches: Rebyota is a rectally-administered suspension; Vowst is an oral capsule containing purified spores. Both eliminate the need for same-day stool donors while meeting pharmaceutical-grade manufacturing standards.
Delivery Routes
FMT can be delivered via multiple routes, each with different engraftment profiles:
- Colonoscopic infusion — Delivers material directly to the cecum/right colon; historically the most studied route with highest per-treatment success rates for C. diff
- Nasogastric/nasoduodenal tube — Upper GI delivery; used in van Nood 2013; associated with slight risk of aspiration
- Enema — Lower GI delivery; Rebyota uses this approach; simpler but may have reduced colonic coverage
- Oral capsules — Frozen capsules enclosing filtered microbiota (Vowst); most patient-friendly; growing evidence base
Microbiome Engraftment
Engraftment — the stable colonization of donor microbes in the recipient gut — is the key to FMT's durability. Studies using 16S rRNA sequencing and shotgun metagenomics show that donor-strain species can be detected in recipients months to years after a single FMT. Engraftment is most robust when:
The recipient's existing microbiome has low diversity (as in post-antibiotic dysbiosis), the donor has a high-diversity microbiome, and delivery reaches the relevant gut segment. In C. diff patients, disruption of commensal bacteria by repeated antibiotic use creates an ecological vacuum that C. difficile exploits — FMT fills that vacuum with competing organisms that produce short-chain fatty acids and secondary bile acids hostile to C. difficile germination.
The C. diff Evidence: van Nood 2013, FDA Approval, and What 90% Really Means
The Landmark Trial: van Nood et al., NEJM 2013
The van Nood trial randomized 43 patients with recurrent or refractory C. difficile infection to one of three arms: duodenal infusion of donor stool after vancomycin pretreatment, vancomycin alone (standard dose), or vancomycin followed by bowel lavage. The FMT arm was stopped after interim analysis showed such overwhelming superiority it was considered unethical to continue.
| Study / Source | Design | Condition | Key Finding | Year |
|---|---|---|---|---|
| van Nood et al. | RCT, NEJM | Recurrent C. diff | 81% FMT cure after 1 tx; ~90% after 2nd; vs 31% vancomycin | 2013 |
| Paramsothy et al. | RCT, Lancet | Ulcerative colitis | 32% FMT remission vs 9% placebo (intensive multi-donor) | 2017 |
| Moayyedi et al. | RCT, Gastroenterology | Ulcerative colitis | 24% remission FMT vs 5% water enema (single donor) | 2015 |
| Kootte et al. | RCT, Cell Metabolism | Metabolic syndrome | Lean-donor FMT improved insulin sensitivity at 6 weeks vs autologous control | 2017 |
| FDA (Rebyota/Vowst) | Phase 3 RCTs | Recurrent C. diff | 70–88% success rate for commercial FMT products vs 58% placebo | 2022–23 |
FDA Approval: Rebyota and Vowst (2022–2023)
The FDA's approval of two FMT-derived products marked a watershed in microbiome medicine. Neither is technically "FMT" in the traditional sense, but both derive from donated human stool and represent the regulatory legitimization of microbiome-based therapeutics.
Rebyota (Ferring Pharmaceuticals) — approved November 2022 — is a rectally-administered suspension for adults with recurrent CDI after antibiotic treatment. Phase 3 data showed a 70.6% treatment success rate versus 57.5% for placebo at 8 weeks.
Vowst (Seres Therapeutics/Nestlé Health Science) — approved April 2023 — is an oral capsule formulation of purified C. diff-resistant spores. The ECOSPOR III trial showed 88% of patients remained CDI-free at 8 weeks versus 60% on placebo — the largest placebo-controlled reduction in CDI recurrence ever demonstrated in a phase 3 trial.
Support Microbiome Recovery: High-Diversity Probiotics
While FMT is a clinical procedure, daily multi-strain probiotics can support microbial diversity during and after antibiotic courses. Look for products with multiple Lactobacillus and Bifidobacterium strains plus documented CFU counts.
🔒 Affiliate link — we earn a small commission at no cost to you. GutCode only recommends products with published research.FMT for IBD: Paramsothy 2017, UC Remission Rates & Crohn's Disease Data
Inflammatory bowel disease presents a more complex challenge than C. diff. Where C. diff is caused by a single pathogen exploiting a depleted microbiome, IBD involves chronic immune dysregulation in which the microbiome is both a contributing factor and a potential therapeutic target — but causality is harder to establish.
Ulcerative Colitis: The Paramsothy 2017 Lancet Trial
The Paramsothy trial was among the most rigorous FMT trials in IBD to date. 81 patients with active UC were randomized to intensive multi-donor FMT (5 donors, delivered via colonoscopy followed by 40 enemas over 8 weeks) or autologous placebo enemas. The results were notable: 32% of FMT recipients achieved steroid-free clinical remission versus 9% in the placebo arm — a 3.5-fold difference.
Crucially, the multi-donor approach appeared important. A companion study (Moayyedi 2015, Gastroenterology) using a single donor showed 24% remission versus 5% — suggesting donor diversity matters and that specific donor-recipient microbiome compatibility may influence outcomes.
Crohn's Disease: Emerging and Mixed Data
Crohn's evidence is thinner and more heterogeneous. A 2017 systematic review by Colman and Rubin found that across 18 studies (mostly open-label or case series), approximately 60% of Crohn's patients showed clinical response, but controlled trial data remains sparse. A 2019 pilot RCT (Paramsothy, Alimentary Pharmacology & Therapeutics) found no significant difference between FMT and placebo in Crohn's — though sample sizes were small.
The mechanistic rationale is sound: Crohn's patients show reduced microbial diversity and depletion of butyrate-producing species like Faecalibacterium prausnitzii and Roseburia intestinalis. Whether FMT can reliably restore these populations and sustain clinical benefit remains an active area of investigation.
FMT and Metabolic Syndrome: The Kootte 2017 Insulin Sensitivity Data
Perhaps the most paradigm-shifting area of FMT research is metabolic disease. The gut microbiome regulates energy harvest, bile acid metabolism, short-chain fatty acid production, and gut-brain signaling — all of which connect to insulin sensitivity, obesity, and metabolic syndrome.
Kootte et al., Cell Metabolism 2017
This randomized controlled trial assigned 38 men with metabolic syndrome to receive either a fecal transplant from lean healthy donors or an autologous transplant (their own stool, as control). At 6 weeks, the lean-donor FMT group showed significantly improved peripheral insulin sensitivity — a key marker of metabolic health — compared to the autologous control group.
Metagenomic analysis confirmed that lean-donor microbiome species, particularly Eggerthella lenta-related taxa and butyrate producers, had partially engrafted in recipients. The effect was modest and did not persist indefinitely, suggesting that dietary and lifestyle inputs continue to shape the microbiome post-transplant — FMT alone is not a permanent metabolic fix.
Germ-Free Mouse Experiments: The Causal Framework
A large body of evidence from germ-free mouse models has helped establish causality — something human observational studies cannot do. In germ-free mice raised without any gut microbiome, researchers can transplant microbiota from obese or lean humans and watch the metabolic phenotype transfer. Gordon et al. (Science, 2013) demonstrated that germ-free mice colonized with microbiota from obese twins gained more fat mass than littermates colonized with lean-twin microbiota — even on identical diets.
These experiments don't prove FMT will cure human obesity, but they establish that the microbiome is causally upstream of certain metabolic outcomes — making it a legitimate therapeutic target.
- Metabolic syndrome & type 2 diabetes — Multiple RCTs examining insulin sensitivity, gut permeability, and SCFA production
- Clostridioides difficile prophylaxis — FMT before anticipated antibiotic courses in high-risk patients
- Cancer immunotherapy enhancement — Early data suggesting donor microbiome influences checkpoint inhibitor response (Baruch et al., Science 2021)
- Depression and neuropsychiatric conditions — Gut-brain axis research; germ-free models show microbiome affects behavior, but human trials are nascent
- Autism spectrum disorder — Preliminary open-label data (Adams et al. 2019); no controlled trial evidence yet
FMT Safety: Donor Screening, Adverse Events & Why DIY FMT Is Dangerous
Donor Screening: What FDA-Approved Products Test For
One of the most important advances the FDA approval brought was standardized donor screening. Approved products screen donors for an extensive panel of pathogens and risk factors, including:
- Bloodborne infections — HIV-1/2, hepatitis B and C, HTLV-1/2, West Nile virus, Chagas disease, Zika virus, syphilis, cytomegalovirus
- Stool pathogens — SARS-CoV-2, norovirus, rotavirus, adenovirus, Salmonella, Shigella, Campylobacter, E. coli O157, C. difficile toxin, Giardia, Cryptosporidium, helminths
- Multi-drug resistant organisms — MRSA, VRE, ESBL-producing enterobacteriaceae, CRE — the most critical safety concern in FMT
- Medical history screening — Recent antibiotic use, IBD, IBS, immunosuppression, recent travel to endemic disease areas, high-risk sexual behavior, recent tattoos/piercings
Known Adverse Events and Serious Risks
In immunocompetent patients receiving FMT via standard clinical channels, serious adverse events are rare. The most common are transient GI symptoms — bloating, cramping, altered bowel habits — that resolve within days. Procedural risks (aspiration during nasogastric delivery, perforation risk with colonoscopy) are tied to the delivery method, not the transplant material itself.
However, serious and life-threatening events have occurred, most notably in immunocompromised patients. In 2019, the FDA issued a safety alert after two immunocompromised patients who received FMT developed bloodstream infections with drug-resistant E. coli (ESBL-producing strains); one patient died. This led to the FDA adding enhanced multi-drug resistant organism screening requirements — requirements that are now standard in all approved products.
DIY FMT: The Serious Dangers
Online communities have promoted DIY FMT using home-prepared donor stool from family members or "tested" online suppliers. This practice is genuinely dangerous and should not be attempted. The risks include:
Transmission of multi-drug resistant organisms that even standard clinical screening may miss; transmission of undetected viral pathogens; improper preparation leading to pathogen concentration; and use in conditions (like IBD) where the evidence base doesn't yet support widespread clinical use. No home preparation can replicate the 50+ pathogen screening panel of FDA-approved products or clinical stool banks.
Support Microbiome Diversity: Prebiotic Fiber Blend
Prebiotic fibers (inulin, FOS, resistant starch, psyllium husk) selectively feed beneficial gut bacteria and support microbial diversity — a foundation for microbiome health whether or not FMT is part of your care plan.
🔒 Affiliate link — we earn a small commission at no cost to you. GutCode only recommends products with published research.8-Step Evidence-Based Gut Reset Protocol: Before and After FMT
FMT is most effective when the gut environment is optimized before and after the procedure. The following protocol is based on published clinical guidance and microbiome research — it is not a replacement for FMT itself, but a framework for maximizing its success.